Scenic Biotech raises $31 million to power pipeline

Amsterdam, Netherlands-based Scenic Biotech has closed a Series A financing of around $31 million.

The company calls itself a pioneer in the discovery of genetic modifiers to enable the development of disease-modifying therapeutics for rare genetic disorders and other devastating illnesses.

"The potential to become one of Europe’s most exciting biotech companies"Funds raised will be used to accelerate Scenic’s transition into a development stage company, advancing its in-house pipeline and supporting the creation of new programs based on its Cell-Seq genetic modifier target discovery platform, including new industry collaborations.